Company: Johnson & Johnson
2016 U.S. sales: $1.27 billion
Drug class: SGLT2
2016 wasn’t the easiest year for Invokana. For one, European regulators began scrutinizing the med over a potential link to toe amputations; in May, the FDA followed up with a black box warning citing an increased risk of leg and foot amputations.
And for two, Johnson & Johnson watched as SGLT2 class rival Jardiance, a med from Eli Lilly and Boehringer Ingelheim, landed a new indication for decreasing the risk of cardiovascular death among high-risk Type 2 diabetes patients.
Questions also swirled around the growth rate of the SGLT2 class in general, and how far it could go.
Still, J&J’s med posted a better sales year than it did in 2015—even if the numbers grew less than they had in the past. Worldwide sales rose to $1.41 billion, marking a 7.6% increase that the company attributed to SGLT2 market growth.
J&J is hoping 2017 can help Invokana ramp up further. It’s expecting its own cardiovascular outcomes data, which, if positive, could help it beat back competition from both Lilly and BI’s med and AstraZeneca’s Farxiga, which will be the last of the bunch to tally outcomes results.